Asahi Kasei Bioprocess and Asahi Kasei Microza Co., Ltd. (AKMH), both affiliated companies of Asahi Kasei Medical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: Ken Shinomiya), hereby wishes to announce that the Asahi Kasei (China) Bioprocess Technical Center (CBTC) celebrated its official opening on November 23, 2023, said the company.
The new Technical Center is located in Suzhou City, Jiangsu Province, People’s Republic of China.
The Bioprocess Division, which focuses on biosafety testing, biopharmaceutical CDMO 1 business development, and the manufacture and sale of bioprocess-related equipment used in the production of biotherapeutics*2, is a rapidly growing division at Asahi Kasei Medical. To strengthen our capability to support customers in China, AKBC was established in 2020 to provide services to the Chinese market and manages the import and sale of Planova™ virus removal filters, BioOptimal™ microfilters and related equipment. In order to expand services through technical advice and support as well as hands-on training for local customers, AKBC opened the CBTC in collaboration with AKMH, which handles the import and sale of MICROZA industrial filtration membranes and systems.
Asahi Kasei Medical contributes to life and living for people around the world as a member of the Asahi Kasei Group’s Health Care Sector, enabling biologics manufacturers to safely and efficiently produce medicines that patients can trust.
We remind, Asahi Kasei's net profit fell by 40% year on year to Yen 30.8 bn in 1H FY 2023 (ended Sep 2023), partly due to demand weakness in China, said the company. The company's basic materials business performed better than prediction, recording an operating profit of Yen 17.7 bn and sales of Yen 610.2 bn.
mrchub.com